Nootropic & Neuropeptides
Dihexa
N-hexanoyl-Tyr-Ile-(6)-aminohexanamide
2 min read · Updated July 27, 2026 · 4 references
Curated by PeptideInfo Wikilast reviewed how we verify
Dihexa is a synthetic angiotensin-IV-derived peptide mimetic studied in cells and animals as a modulator of HGF/c-Met signalling; human efficacy and safety have not been established.
Evidence: Evidence is largely animal/cell studies, not humans.
- Mechanistic and efficacy evidence is preclinical
- No established human dose or approved therapeutic use
- Animal results cannot establish cognitive benefit or safety in people
Dihexa is a synthetic angiotensin-IV-derived peptide mimetic studied in cells and animals as a modulator of HGF/c-Met signalling; human efficacy and safety have not been established.
Overview
Dihexa is a synthetic derivative of an angiotensin IV-related peptide. It was designed to be more metabolically stable and brain-accessible than its peptide predecessors. The reviewed evidence consists of biochemical, cell-culture and animal experiments; it does not demonstrate a clinical benefit in humans.
Preclinical evidence only
Claims about memory, neuroregeneration or dementia treatment go beyond the evidence. No human efficacy or safety study is cited in this reviewed source set.
Identity and chemistry
| Property | Verified value |
|---|---|
| PubChem CID | 129010512 |
| Molecular formula | C27H44N4O5 |
| Molecular weight | 504.7 g/mol |
| CAS number | 1401708-83-5 |
PubChem names the compound N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide. It is peptide-derived, but is not a conventional long amino-acid-chain peptide.
Proposed mechanism
A 2014 study reported that dihexa bound hepatocyte growth factor (HGF), increased HGF-dependent c-Met phosphorylation and promoted spinogenesis and synaptogenesis in neuronal preparations. The effects were reduced by an HGF antagonist or c-Met-directed interference. These findings support an HGF/c-Met-dependent hypothesis, not a clinically validated mechanism in people.
Research evidence
In the same research programme, orally administered dihexa was tested in a scopolamine rat model of impaired spatial learning. A later APP/PS1 mouse study reported changes in cognitive testing and PI3K/AKT signalling. Another experiment studied protection of zebrafish lateral-line hair cells after aminoglycoside exposure.
All three models are useful for hypothesis generation, but none is a human trial. Model-specific behavioural or tissue findings cannot be converted directly into claims about Alzheimer disease, hearing loss or cognition in people.
Clinical and regulatory context
The reviewed sources do not include a human clinical trial, an FDA-approved label or an EMA-authorised product for dihexa. This page therefore classifies it as preclinical. That classification describes the evidence reviewed here and is not a universal legal determination.
Safety and uncertainty
Human pharmacokinetics, adverse-event frequency, interaction risk, reproductive safety and long-term effects remain uncharacterised in the reviewed evidence. Because HGF/c-Met signalling participates in cell growth, motility and repair, theoretical discussion of that pathway is not a substitute for toxicology or clinical safety data.
Dosing
No human regimen is established. Doses used in rodents or cell concentrations are experimental methods and are intentionally not presented as a conversion guide.
No human dosing standard
An animal dose cannot be made into a safe human dose by simple weight conversion.
Evidence conclusion
Dihexa has a defined chemical identity and a coherent preclinical HGF/c-Met research hypothesis. The decisive missing layer is controlled human evidence covering exposure, safety and clinically meaningful outcomes.
References
Frequently asked questions
- What is Dihexa?
- Dihexa is a synthetic angiotensin-IV-derived peptide mimetic studied in cells and animals as a modulator of HGF/c-Met signalling; human efficacy and safety have not been established.
- Is Dihexa approved as a medicine, and where?
- No. Dihexa is not approved for human use. The available evidence comes almost entirely from laboratory and animal studies.
- What is Dihexa studied for?
- Dihexa is most often discussed in the context of cognition, mood & sleep. Being studied for an area does not mean it is proven or approved for it.
- Does Dihexa have human clinical trials?
- No. The evidence for Dihexa is almost entirely from cell and animal studies; there are no established human clinical trials.
Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Dihexa is a research chemical not approved for human use. Consult a qualified healthcare professional before making health decisions.